Subscribe
Home
Issues
Online First
Latest Issue
Issue Archive
Special Issues
Browse By Topic
Personalized Medicine
Economics & Value
FDA Approvals, News & Updates
COVID-19
Cholangiocarcinoma
View All Topics ›
Conference Correspondent
SABCS 2023 - HER2+ MBC
ASCO 2023 - Breast Cancer
Web Exclusives
Web Exclusive Articles
Videos
Interview with the Innovators
Prostate Cancer Diagnostics Monthly Minutes
Webinars
Quick Quizzes
Press Releases
AVBCC
Association for Value-Based Cancer Care
VBCM
Value-Based Care in Myeloma
Browse By Topic
Cholangiocarcinoma
Cholangiocarcinoma
Highlights From the 5th Annual Cholangiocarcinoma Summit
By
Ashley Gamble, PharmD
Cholangiocarcinoma
December 2023, Vol 14, No 6
The 5th Annual Cholangiocarcinoma Summit, held October 19 to 21, 2023, in Scottsdale, AZ, brought together experts from around the world to discuss the latest research and clinical data pertaining to the diagnosis and treatment of patients with CCA and other biliary track cancers.
Read Article
Physician Debate: Is Chemotherapy Still the Backbone for CCA Treatment?
Cholangiocarcinoma
August 2023, Vol 14, No 4
At the 10th Annual Cholangiocarcinoma Foundation Conference, Rachna Shroff, MD, MS, Chief, Gastrointestinal Medical Oncology, and Director, Clinical Trials Office, University of Arizona Cancer Center, Tucson, and Madhulika Eluri, MD, Hematology/Oncology Fellow, The University of Texas MD Anderson Cancer Center, Houston, debated whether chemotherapy remains the backbone for cholangiocarcinoma (CCA) treatment or if it is time to move away from this therapeutic strategy.
Read Article
Cost-Effectiveness of GemCis with or without Durvalumab in Patients with Advanced Cholangiocarcinoma
Cholangiocarcinoma
April 2023, Vol 14, No 2
First-line standard of care for patients with advanced cholangiocarcinoma has evolved from a chemotherapy-only regimen with gemcitabine/cisplatin to include the immune checkpoint inhibitor durvalumab based on results from TOPAZ-1 showing that the addition of durvalumab improved progression-free survival and overall survival compared with GemCis alone.
Read Article
Researchers Predict Rise in the Incidence of Cholangiocarcinoma Over the Next 10 Years
Cholangiocarcinoma
April 2023, Vol 14, No 2
Cholangiocarcinoma (CCA), a rare and aggressive form of cancer, has seen a steady increase in incidence in the United States, with a predominant increase in intrahepatic CCA, from 2001 to 2017, according to a recent epidemiological study.
Read Article
Supportive Care and Management of Complications in BTCs: A Multidisciplinary Team Approach
Cholangiocarcinoma
February 2023, Vol 14, No 1
At the 4th Annual Cholangiocarcinoma Summit, held on October 13-15, 2022, in Aurora, CO, experts in the field of gastroenterology, interventional radiology, nursing, and surgery discussed the importance of using a multidisciplinary approach to supportive care and the management of complications in patients with biliary tract cancers (BTCs).
Read Article
GemCis with or without CPI-613 as First-Line Therapy for Patients with Advanced BTCs: The BilT-04 Study
Cholangiocarcinoma
October 2022, Vol 13, No 5
Patients with advanced biliary tract cancers (BTCs) have a poor prognosis despite systemic chemotherapy.
Read Article
Family History of Primary Liver Cancer Associated with Increased Risk for Extrahepatic CCA
Cholangiocarcinoma
June 2022, Vol 13, No 3
The subtypes of cholangiocarcinoma (CCA), including intrahepatic CCA and extrahepatic CCA, have various underlying tumor microenvironments, pathobiology, epidemiologic features, and risk factors; however, the genetic underpinnings of the CCA subtypes have not been previously defined.
Read Article
TOPAZ-1: Durvalumab plus Gemcitabine and Cisplatin in Advanced Biliary Tract Cancer
Cholangiocarcinoma
June 2022, Vol 13, No 3
The global, double-blind, placebo-controlled, phase 3 TOPAZ-1 clinical trial evaluated the first-line chemoimmunotherapy regimen of the PD-L1 inhibitor durvalumab (Imfinzi) plus gemcitabine and cisplatin in patients with advanced biliary tract cancer.
Read Article
The International Cholangiocarcinoma Research Network Program Initiatives
Cholangiocarcinoma
April 2022, Vol 13, No 2
The International Cholangiocarcinoma Research Network (ICRN) is a program initiated by the Cholangiocarcinoma Foundation (CCF).
Read Article
Role of Radiology in Intrahepatic Cholangiocarcinoma Addressed at the 2021 Interventional Oncology Meetings
Cholangiocarcinoma
October 2021, Vol 12, No 5
Key topics related to intrahepatic cholangiocarcinoma (CCA) were presented at the 2021 Society of Interventional Oncology (SIO) and the Society of Interventional Radiology (SIR) meetings and were discussed during the CCA Summit. Bruno C. Odisio, MD, FSIR, Interventional Radiologist and Co-Director of Research, Department of Interventional Radiology, M.D. Anderson Cancer Center, Houston, TX, reviewed the significance of these findings.
Read Article
Page 1 of 5
1
2
3
4
5
View the Latest Issue of VBCC
Read Issue
Home
Issues
Online First
Latest Issue
Issue Archive
Special Issues
Browse By Topic
Personalized Medicine
Economics & Value
FDA Approvals, News & Updates
COVID-19
Cholangiocarcinoma
View All Topics ›
Conference Correspondent
SABCS 2023 - HER2+ MBC
ASCO 2023 - Breast Cancer
Web Exclusives
Web Exclusive Articles
Videos
Interview with the Innovators
Prostate Cancer Diagnostics Monthly Minutes
Webinars
Quick Quizzes
Press Releases
AVBCC
Association for Value-Based Cancer Care
VBCM
Value-Based Care in Myeloma